Oruka Therapeutics, Inc. (ORKA) Institutional Ownership

Ownership Summary

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has 141 institutional investors with active 13F positions as of December 2025.

• Their combined ownership stood at 118.5% of outstanding shares in December 2025, up from 103.6% in September 2025.
• Their total shares held in ORKA increased 16.32% from the prior quarter, while the number of investors in Oruka Therapeutics increased 113.64% year over year.
• Activity in ORKA broke down as 98 buyers, 18 sellers, and 25 unchanged among 141 total holders.
• Combined, these investors held 52.23Mn shares in ORKA for December 2025, up by 7.33Mn shares quarter on quarter, and up 20.47Mn shares year over year.
• FMR LLC holds the largest position in ORKA at 7.43Mn shares as of December 31, 2025, or 16.86% of shares outstanding.
• The most significant purchases of ORKA for the quarter ending December 2025 came from VANGUARD CAPITAL MANAGEMENT LLC (1.86Mn), PRICE T ROWE ASSOCIATES INC /MD/ (727.45K), Paradigm Biocapital Advisors LP (610.0K), Bellevue Group AG (507.01K), VANGUARD PORTFOLIO MANAGEMENT LLC (350.89K).
• Leading sellers of Oruka Therapeutics shares for the quarter ending December 2025 were Affinity Asset Advisors, LLC (302.67K), Cable Car Capital, LP (200.0K), Soleus Capital Management, L.P. (185.0K), Deep Track Capital, LP (127.31K), Barclays Plc (87.59K).
• Business Quant data shows the 10 biggest positions in Oruka Therapeutics as of December 2025 are held by FMR LLC (7.43Mn), Venrock Adviser, LLC (4.15Mn), Fairmount Funds Management LLC (3.71Mn), BlackRock, Inc. (3.53Mn), VIKING GLOBAL INVESTORS LP (2.67Mn), Paradigm Biocapital Advisors LP (2.32Mn), RTW INVESTMENTS, LP (2.06Mn), Deep Track Capital, LP (2.03Mn), Remedium Capital Partners, LLC (1.89Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.86Mn).